Endothelial progenitors are a population of cells with the inherent capacity to differentiate into mature endothelial cells and proangiogenic paracrine action. These characteristics have led to extensive studies being performed and tested in the treatment of tissue ischemia. The natural course of diabetes mellitus (DM) results in multiple areas of vascular damage. Thus endothelial progenitor cells'(EPCs) beneficial potential is particularly desirable in diabetic patients. In this review, we summarize contemporary knowledge of EPC biology in DM. It has been shown that EPC functions are considerably impaired by DM. The presence of peripheral arterial disease (PAD) seems to further exacerbate the deficiencies of EPCs. However, studies examining EPC counts in PAD and DM observed disparate results, which can be due to a lack of consensus on precise EPC immunotype used in the different studies. Nevertheless, the results of EPC-based autologous cell therapy (ACT) are promising. In addition, EPCs have been shown to bean independent predictor of cardiovascular risk and diabetic foot ulcer healing.
- MeSH
- Cell- and Tissue-Based Therapy methods MeSH
- Cell Differentiation * MeSH
- Diabetes Mellitus therapy MeSH
- Endothelial Progenitor Cells cytology MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Peripheral Arterial Disease therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Kritická končetinová ischemie (CLI) limituje úspěšnost léčby defektů u pacientů se syndromem diabetické nohy (SDN). Až u 50 % těchto pacientů není možné provést standardní revaskularizaci (perkutánní transluminální angioplastikou (PTA) nebo bypassem), jedná se o tzv. no-option CLI (NOCLI), která může být indikací k autologní buněčné terapii (ABT). Cílem sdělení je demonstrovat bezpečnost a dlouhodobý efekt ABT u pacientky s NOCLI. Pacientka byla léčena ABT jako jedna z prvních v našem centru v roce 2008. 42 měsíců po ABT došlo k trvalému zhojení vícečetných defektů postižené končetiny. K významnému zlepšení parametrů ischemie došlo 3 měsíce po ABT a přetrvává nyní víc než 8 let.
Critical limb ischemia (CLI) is a main factor limiting wound healing in patients with diabetic foot disease (DFD). Up to 50% of these patients are not eligible for standard revascularization procedures (percutaneous transluminal angioplasty or bypass) thereby defined as "no-option" CLI (NOCLI). Autologous cell therapy (ACT) has emerged as a perspective alternative treatment of NOCLI. The aim of this case report is to demonstrate safety and long-term effect of ACT in a patient with NOCLI. The patient received ACT among the first in our centre in 2008. Multiple ulcers of the impaired foot healed 42 months later with persistent effect. Significant ischemia improvement was recorded 3 months after ACT and has been lasting so far for more than 8 years.
- MeSH
- Transplantation, Autologous methods MeSH
- Diabetes Mellitus, Type 1 complications MeSH
- Diabetic Foot * therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Peripheral Arterial Disease etiology surgery MeSH
- Cell Transplantation methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
Kritická končetinová ischemie (CLI) limituje úspěšnost léčby defektů u pacientů se syndromem diabetické nohy (SDN). Až u 50 % těchto pacientů není možné provést standardní revaskularizaci (perkutánní transluminální angioplastikou (PTA) nebo bypassem), jedná se o tzv. no-option CLI (NOCLI), která může být indikací k autologní buněčné terapii (ABT). Cílem sdělení je demonstrovat bezpečnost a dlouhodobý efekt ABT u pacientky s NOCLI. Pacientka byla léčena ABT jako jedna z prvních v našem centru v roce 2008. 42 měsíců po ABT došlo k trvalému zhojení vícečetných defektů postižené končetiny. K významnému zlepšení parametrů ischemie došlo 3 měsíce po ABT a přetrvává nyní víc než 8 let.
Critical limb ischemia (CLI) is a main factor limiting wound healing in patients with diabetic foot disease (DFD). Up to 50% of these patients are not eligible for standard revascularization procedures (percutaneous transluminal angioplasty or bypass) thereby defined as "no-option" CLI (NOCLI). Autologous cell therapy (ACT) has emerged as a perspective alternative treatment of NOCLI. The aim of this case report is to demonstrate safety and long-term effect of ACT in a patient with NOCLI. The patient received ACT among the first in our centre in 2008. Multiple ulcers of the impaired foot healed 42 months later with persistent effect. Significant ischemia improvement was recorded 3 months after ACT and has been lasting so far for more than 8 years.
- MeSH
- Transplantation, Autologous MeSH
- Cell- and Tissue-Based Therapy methods MeSH
- Diabetes Mellitus, Type 1 complications MeSH
- Diabetic Foot diagnostic imaging surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Treatment Failure MeSH
- Peripheral Arterial Disease surgery MeSH
- Bone Marrow Transplantation methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
